Equities
  • Price (EUR)18.03
  • Today's Change0.47 / 2.68%
  • Shares traded0.00
  • 1 Year change+14.55%
  • Beta--
Data delayed at least 15 minutes, as of Jan 17 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, science, video and other products. The Company operates in five business segments. The Endoscopy segment provides gastrointestinal endoscopy, surgical endoscopy, endoscopy systems and repair services. The Therapeutic Equipment segment provides endoscopic treatment tools, energy devices, urology, gynecology and otolaryngology products. The Scientific segment provides biological microscope, industrial microscope, industrial endoscope and non-destructive inspection equipment. The Imaging segment provides digital cameras and recording machines. The Others segment is engaged in the manufacture and sale of biomaterials. The Company is also engaged in the financial investment business.

  • Revenue in JPY (TTM)827.10bn
  • Net income in JPY102.14bn
  • Incorporated1919
  • Employees31.65k
  • Location
    Olympus CorpShinjuku Monolith, 2-3-1, Nishi-ShinjukuSHINJUKU-KU 163-0914JapanJPN
  • Phone+81 333402111
  • Fax+81 333402062
  • Websitehttps://www.olympus.co.jp/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.